REBECCA project aims to tap into the potential of real-world data to support clinical research and to improve existing clinical workflows.
The project will combine clinical data with data describing patients’ real-life behaviour including physical activity, eating habits, sleep and online interactions. These new forms of real-world data will be collected via mobile and wearable devices. Novel functional and emotional indices will be produced for each individual and used to examine patient status and quality of life. REBECCA will use these indices for optimising patient care and as complementary outcomes during clinical research.
REBECCA 360º platform, a combination of minimally obtrusive, non-stigmatising mobile applications, will be offered to breast cancer survivors as a means of supporting their everyday life and enhancing their interaction with health experts. The platform will be deployed within 7 clinical studies in Norway, Spain, and Sweden, involving over 650 individuals, and it will help shape future guidelines and practices for post-cancer treatment. Best practices resulting from the studies will be disseminated to researchers, public health and regulatory bodies throughout Europe.
REBECCA brings together 12 partners from 7 European countries: Cyprus, Belgium, Greece, Luxemburg, Norway, Spain and Sweden.
INCLIVA will conduct the study to improve research on cancer treatment-induced osteopathy and the intervention study to improve clinical management and patient outcomes through detailed monitoring of REBECCA. The latter will assess improvements in patient-reported quality of life and treatment satisfaction in breast cancer patients as a result of a flexible treatment plan supported by real-world data collected by REBECCA, in comparison with standard care.
REBECCA has received funding from the European Union’s Horizon 2020 research and innovation programme under the grant agreement No 965231.